健帆生物
(300529)
| 流通市值：155.69亿 | | | 总市值：242.62亿 |
| 流通股本：5.12亿 | | | 总股本：7.99亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,195,690,243.92 | 1,495,624,529.8 | 744,336,658.85 | 1,922,348,169.84 |
| 营业收入 | 2,195,690,243.92 | 1,495,624,529.8 | 744,336,658.85 | 1,922,348,169.84 |
| 二、营业总成本 | 1,282,068,331.55 | 861,393,672.66 | 421,939,785.99 | 1,420,642,392.89 |
| 营业成本 | 410,333,473.21 | 291,105,613.64 | 158,657,760.64 | 383,984,114.88 |
| 税金及附加 | 35,054,795.5 | 23,972,478.38 | 11,666,287.33 | 31,815,500.13 |
| 销售费用 | 510,257,725.2 | 340,764,543.02 | 158,497,751.13 | 615,973,703.02 |
| 管理费用 | 128,708,141.07 | 84,668,750.75 | 38,469,986.54 | 177,386,061.47 |
| 研发费用 | 174,715,744.33 | 112,785,154.32 | 54,171,638.09 | 245,378,745.01 |
| 财务费用 | 22,998,452.24 | 8,097,132.55 | 476,362.26 | -33,895,731.62 |
| 其中:利息费用 | 47,947,089.05 | 32,560,826.4 | 16,352,930.47 | 54,333,084.61 |
| 其中:利息收入 | 26,133,443.83 | 24,543,477.7 | 15,651,888.8 | 87,960,343.26 |
| 加:公允价值变动收益 | 334,745.17 | 5,802,775.48 | 1,014,555.55 | 0 |
| 加:投资收益 | 24,694,421.65 | 8,179,293.09 | 2,528,325.71 | 0 |
| 资产处置收益 | 2,372,652.83 | 2,163,697.06 | 1,277,839.47 | 6,719,584.13 |
| 资产减值损失(新) | -15,321.9 | - | 0 | -28,182,434.2 |
| 信用减值损失(新) | -8,725,141.9 | -7,914,835.48 | -1,275,840.74 | 8,229,357.83 |
| 其他收益 | 52,078,282.13 | 34,521,804.09 | 22,775,130.57 | 55,346,933.24 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 984,361,550.35 | 676,983,591.38 | 348,716,883.42 | 543,819,217.95 |
| 加:营业外收入 | 107,093.06 | 99,454.3 | 62,172.85 | 322,339.94 |
| 减:营业外支出 | 29,849,134.39 | 16,830,487.49 | 8,844,650.12 | 23,121,493.51 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 954,619,509.02 | 660,252,558.19 | 339,934,406.15 | 521,020,064.38 |
| 减:所得税费用 | 165,792,667.72 | 109,496,807.52 | 56,006,226.11 | 95,296,913.33 |
| 六、净利润 | 788,826,841.3 | 550,755,750.67 | 283,928,180.04 | 425,723,151.05 |
| 持续经营净利润 | 788,826,841.3 | 550,755,750.67 | 283,928,180.04 | 425,723,151.05 |
| 归属于母公司股东的净利润 | 791,634,115.46 | 552,505,833.05 | 284,766,143.1 | 436,492,212.29 |
| 少数股东损益 | -2,807,274.16 | -1,750,082.38 | -837,963.06 | -10,769,061.24 |
| (一)基本每股收益 | 0.99 | 0.69 | 0.35 | 0.55 |
| (二)稀释每股收益 | 0.97 | 0.68 | 0.35 | 0.57 |
| 八、其他综合收益 | - | - | - | 26,930,819.4 |
| 归属于母公司股东的其他综合收益 | - | - | - | 26,930,819.4 |
| 九、综合收益总额 | 788,826,841.3 | 550,755,750.67 | 283,928,180.04 | 452,653,970.45 |
| 归属于母公司股东的综合收益总额 | 791,634,115.46 | 552,505,833.05 | 284,766,143.1 | 463,423,031.69 |
| 归属于少数股东的综合收益总额 | -2,807,274.16 | -1,750,082.38 | -837,963.06 | -10,769,061.24 |
| 公告日期 | 2024-10-19 | 2024-08-08 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |